Generic drugs in Canada: an examination of tiered pricing

Hollis, Aidan
October 2015
CMAJ: Canadian Medical Association Journal;10/6/2015, Vol. 187 Issue 14, p1033
Academic Journal
journal article
The author comments on the deal finalized by the Council of the Federation with generic drug manufacturers to reform the reimbursement scheme for generic drugs. Topics covered include the concept of the tiered pricing scheme, the consequences of the ad hoc price reductions pursued by provincial drug plans in the generic drug market and the possible effect of tendering on incentives to challenge patents on existing brand name drugs.


Related Articles

  • Adhering to generic cholesterol-lowering drugs is associated with lower overall costs of care.  // Formulary;Jun2013, Vol. 48 Issue 6, p202 

    The article reports on topics which were discussed at a presentation which was given by Patrick Gleason of Prime Therapeutics at the Academy of Managed Care Pharmacy's 25th Annual Meeting & Expo, which was held in April of 2013 in San Diego, California. In the presentation Gleason discussed...

  • Saving your health-care dollars.  // Consumer Reports on Health;Jan2009, Vol. 21 Issue 1, p3 

    The article provides tips on how to lower medical expenses in the U.S. It notes that telling doctors that cost matters will make them hold off on nonessential tests and treatments and cut drug costs by just merely prescribing generic than brand-name medications. Furthermore, looking for discount...

  • Generic substitutions may be more costly in the long run. Lindstrom, Richard L. // Ocular Surgery News;5/25/2011, Vol. 29 Issue 10, p3 

    The article comments on the potential negative effects of the use of generic substitutions in treating eye diseases in the U.S. The author argues that medical experts in the country support the cost-effective practice of medicine, however in the case of sight-threatening illnesses, generic...

  • How To Turn 8 Pennies Into $600. Faloon, William // Life Extension;Sep2014, p1 

    The author discusses his research on the cost of active pharmaceutical ingredients for the topical ointment acyclovir in the U.S. Topics covered include the collusion among pharmaceutical companies in denying low-cost rivals access to the marketplace, and recommendations for the government on...

  • Healthcare Costs Associated with Switching from Brand to Generic Levothyroxine. Katz, Michael; Scherger, Joseph; Conard, Scott; Montejano, Leslie; Chang, Stella // American Health & Drug Benefits;Mar2010, Vol. 3 Issue 2, p127 

    Background: Controversy exists over the true therapeutic equivalence of branded and generic levothyroxine-the drug of choice for treating hypothyroidism-so professional societies recommend against switching between different formulations of the drug and suggest that patients who do switch be...

  • Abuse of REMS drives up healthcare costs. MONKS, RICHARD // Drug Store News;8/25/2014, Vol. 36 Issue 8, p90 

    The article discusses the abuse use of risk evaluation and mitigation strategies (REMS) by drug makers in the U.S. that affects the generic drug industry. Topics include the "Prescription Drug Savings from Use of REMS Programs to Delay Generic Market Entry" study reveals the impact of the abuse...

  • Pharmacy Intervention. Major, Meg // Progressive Grocer (India Edition);Oct2013, Vol. 92 Issue 10, p154 

    The article discusses transformative changes for pharmacy operations in the U.S. Topics discussed include initiation of the Affordable Healthcare Act, decline in medicine use and costs due to influx of new generic drugs and fewer patient health care visits and growing competition between...

  • Biogenerics in China: An Evolving Industry. Langer, Eric // BioPharm International;Jun2007, Vol. 20 Issue 6, p26 

    The article discusses the implications of rapid development of the biopharmaceutical industry in China. It is stated that the development plays a significant role in the biogenerics industry. Biogenerics move towards regulatory expansion for the presence of a substantial biogenerics industry in...

  • Healthy competition.  // CMAJ: Canadian Medical Association Journal;2/3/2009, Vol. 180 Issue 3, p283 

    The article offers information on the competition in the generic drug market in the United States. The federal Competition Bureau reports that business entities in the pharmaceutical sector could expect a healthy competition and increased annual savings. The expected increased annual income...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics